

QIBA Lung Nodule Assessment in CT Screening Writing Group

09 November 2012 at 10 AM CST

Call Summary

In attendance:

Samuel G. Armato, III, PhD (Co-Chair)
James L. Mulshine, MD (Co-Chair)
Andrew J. Buckler, MS
Anand Devaraj, MBBS

Ella A. Kazerooni, MD
Michael McNitt-Gray, PhD
Matthijs Oudkerk, MD, PhD

RSNA:

Fiona Miller
Joe Koudelik
Madeleine McCoy

General Discussion

- The CT Technical Committee's Advanced Disease Profile has been circulated with modifications made by Drs. Gierada and Mulshine. Profile version also available on the QIBA Wiki at:
http://qibawiki.rsna.org/index.php?title=CT_Volumetry_tech_ctte
- Goals for the call included:
 - Revisiting the group's name: currently the "Lung Nodule Assessment in CT Screening Writing Group"
 - Key terms in the name may include: initial detection, screening limits, surveillance, monitoring, follow-up and characterization of growth. Additional discussion is required.
 - Establish whether screening or detection is the focus of the group and whether a single Profile could accommodate both.
 - Development of a mission statement
 - Drs. Armato, Gierada, Mulshine and Sullivan to discuss the focus of the group.
 - The inclusion of more International Screening Trial representatives to join the t-cons was suggested; NLST, Nelson Trial, the "Italian" group, ELCAP and the UK Lung Cancer Screening Trial (UKLS).

Next steps

- Drs. Armato, Gierada, Mulshine and Sullivan to discuss focus of the group offline and to establish a mission statement to be shared with the group
- Invite additional representatives from International Screening Trials
- Next call scheduled for: Friday, Dec 7th at 10 AM CT